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ABSTRACT: Dapagliﬂozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged as a promising
neuroprotective agent in murine models of epilepsy and obesity-induced cognitive impairment through its marked antioxidant/
antiapoptotic features. However, the impact of dapagliﬂozin on the pathogenesis of Parkinson’s disease (PD) is lacking. Hence, the
present study aimed at exploring the potential neuroprotective eﬀects of dapagliﬂozin against PD-associated neurodegenerative
aberrations/motor dysfunction in rotenone-induced PD rat model. Rotenone (1.5 mg/kg) was subcutaneously administered every
other day for 3 weeks. The expression of target signals was investigated using qPCR, Western blotting, ELISA, and
immunohistochemistry. Dapagliﬂozin (1 (mg/kg)/day, by gavage for 3 weeks) attenuated PD motor dysfunction and improved
motor coordination in the open-ﬁeld and rotarod tests without triggering hypoglycemia. It also diminished the histopathologic
alterations and α-synuclein expression and augmented tyrosine hydroxylase and dopamine levels. Dapagliﬂozin markedly alleviated
neuronal oxidative stress via lowering lipid peroxides with consequent restoration of the disturbed DJ-1/Nrf2 pathway. Moreover,
dapagliﬂozin counteracted ROS-dependent neuronal apoptosis and upregulated GDNF and its downstream PI3K/AKT/GSK-3β
(Ser9) pathway. Meanwhile, it suppressed neuroinﬂammation via curbing the activation of NF-κB pathway and TNF-α levels.
Together, these pleiotropic neuroprotective eﬀects highlight the promising role of dapagliﬂozin in the management of PD.
KEYWORDS: Dapagliﬂozin, rotenone, neuroinﬂammation, AKT, GSK-3β, Nrf2

■

INTRODUCTION

The exact molecular mechanisms for PD pathogenesis are
not well-deﬁned. However, reactive oxygen species (ROS)associated mitochondrial dysfunction/ATP depletion is a chief
hallmark that mediates the selective loss of dopaminergic
neurons in PD.3 Meanwhile, ROS-dependent apoptosis and
neuronal inﬂammation have been reported to play crucial roles

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder that aﬀects the elderly.1
The primary pathological hallmark of PD involves progressive
and selective loss of dopaminergic (DA) neurons and
accumulation of cytoplasmic protein aggregates known as
Lewy bodies (LB) which comprise α-synuclein protein ﬁbrils
in several brain regions of PD patients.2 When the number of
DA neurons falls below 20−40%, the classical motor and
behavioral disturbances of PD are manifested, e.g., bradykinesia, rigidity, resting tremors, and postural instability. Several
genetic and environmental factors including the exposure to
pesticides are involved in the pathogenesis of PD.3
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Figure 1. Dapagliﬂozin attenuates the motor dysfunction in rats with rotenone-induced PD. The motor performance was assessed by the open-ﬁeld
test, while the motor coordination was examined using the rotarod test. Rotenone was subcutaneously injected as 11 subcutaneous injections (1.5
mg/kg) every other day over 3 weeks span, while dapagliﬂozin (1 (mg/kg)/day) was given by the oral gavage daily over the same period. Openﬁeld test: (A) total traveled distance; (B) mean speed; (C) line crossings; (D) rearing frequency; (E) immobility time; (F) representative track
plots of rats during the open-ﬁeld test. Rotarod test: (G) fall-oﬀ latency. (H) blood glucose levels. The parametric data (total traveled distance,
mean speed, immobility time, fall-oﬀ latency, and blood glucose levels) are presented as the mean ± SEM, while the nonparametric data (line
crossings and rearing frequency) are presented as the median with interquartile range; n = 6−10; *P < 0.05, statistical signiﬁcance against the
control group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

in the progression of PD.3−5 The phosphoinositide 3-kinase
(PI3K)/protein kinase B (AKT) pathway has been characterized to play a pivotal role in regulating cell proliferation and
survival. It has been established that the dysregulation of
PI3K/AKT signaling is implicated in PD pathogenesis where
low p-AKT levels have been described in the DA neurons of
post-mortem PD patients.6 The glycogen synthase kinase-3β
(GSK-3β) is a multifunctional kinase essential for various

cellular functions, such as cell proliferation, diﬀerentiation, and
apoptosis. It plays a crucial role in PD pathogenesis where it
serves as a proinﬂammatory/proapoptotic kinase downstream
of the PI3K/AKT pathway. Of note, phosphorylation of GSK3β at Tyr216 has been reported to activate its proinﬂammatory/proapoptotic actions, whereas its phosphorylation at Ser9
has been reported to block these deleterious eﬀects.3 In the
context of neuroinﬂammation, GSK-3β activates several
B

https://dx.doi.org/10.1021/acschemneuro.0c00722
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience

pubs.acs.org/chemneuro

transcription factors, including the nuclear factor κB (NF-κB)
pathway, which instigates robust proinﬂammatory events.
Activated NF-κB triggers the production of an array of
proinﬂammatory cytokines, e.g., tumor necrosis factor-α
(TNF-α), which provokes DA neuronal death.3,7 Conversely,
the glial cell line-derived neurotrophic factor (GDNF), a
member of the transforming growth factor superfamily, is a
potent trophic agent that promotes the survival and diﬀerentiation of DA neurons through the activation of the
downstream PI3K/AKT pathway.8
Rotenone, a pesticide that inhibits mitochondrial complex I,
has been widely used to induce several pathological changes
and motor dysfunction of PD in rats. By virtue of its
hydrophobicity, rotenone readily crosses the blood−brain
barrier, and its chronic administration, particularly at lower
doses, has been reported to incur selective degeneration of the
nigrostriatal DA neurons. These deleterious actions are
mediated via prompting mitochondrial oxidative stress, ATP
depletion, and apoptosis.1 Besides triggering DA neuronal
degeneration, rotenone elicits LB formation and α-synuclein
deposition. Generally, the rotenone-induced PD model meets
the expectations of research studies on PD by recapitulating
several anatomical, neurochemical, behavioral, and neuropathological features of the human condition.9
To date, the mainstay treatment strategies for PD focus on
addressing the symptoms via enhancement of the dopaminergic eﬀects without aﬀecting the inevitable progressive neurodegeneration associated with the disease. Patients with PD
continue to suﬀer a higher rate of mortality compared to the
general population;1 thus, the search for eﬀective agents that
can aﬀect the disease progression merits attention. The newly
developed sodium-glucose-linked transporter 2 (SGLT2)
inhibitors are novel agents for the management of type 2
diabetes mellitus where they improve glycemic control with a
minimum risk of hypoglycemia. The concept that the
inhibition of renal SGLT2 results in glucosuria and diuresis
without triggering hypoglycemia has been previously demonstrated by the pathogenesis of familial renal glucosuria. In that
disorder, the genetic mutation of the SGLT2 gene has been
manifested by glucosuria and diuresis, yet the blood glucose
remains normal.10,11 Beyond their glucose-lowering ability,
SGLT2 inhibitors have displayed marked reno- and
cardioprotective features in diabetic patients and experimental
animals.11 In the context of neuroprotection, SGLT2 inhibitors
have improved the cognitive function in diabetic (db/db) mice
via abrogation of cerebral oxidative stress12 and in high-fat diet
(HFD)-fed mice through suppression of obesity-associated
neuroinﬂammation.13
Dapagliﬂozin (DPG) is a selective/potent SGLT2 inhibitor
that has demonstrated glucose-lowering eﬀects in type 2
diabetes mellitus with a low risk of hypoglycemia.14 Even in
normoglycemic animals, DPG has not lowered the blood
glucose levels, as demonstrated in rats with coronary ligationinduced myocardial infarction.15 With regard to its neuroprotective features, DPG has attenuated the cognitive decline
in HFD-fed rats,16 the seizure activity in a murine model of
pentylenetetrazol (PTZ)-induced epilepsy,17 and the behavioral dysfunction in Huntington’s disease in rats18 and
improved the recognition memory in diabetic mice.19 In fact,
the expression of SGLT2 in the mammalian central nervous
system (CNS) has been demonstrated, where signiﬁcant
SGLT2 expression is characterized in endothelial cells of the
blood−brain barrier (BBB), cerebellum, and hippocampus.20
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Notably, SGLT2 inhibitors, including DPG, are lipid-soluble
drugs that can cross the BBB and access the CNS, especially
under the inﬂammatory neurological conditions, including
PD.20−22 In perspective, DPG attenuated the neuroinﬂammatory and apoptotic events in the brain striata of rats with
Huntington’s disease, conﬁrming the ability of DPG to cross
the BBB.18 Likewise, DPG ameliorated brain oxidative stress,
mitochondrial dysfunction, apoptosis, inﬂammation, and
hippocampal synaptic plasticity in the brain of rats with
HFD-evoked cognitive decline.16 Despite these promising
neuroprotective eﬀects, the potential of DPG for the
amelioration of rotenone-induced PD has not been previously
examined. Thus, the present work aimed to investigate the
potential of DPG to attenuate neuronal injury and motor
dysfunction in rotenone-evoked PD model in rats. Given that
hyperglycemia has been described to contribute to the
neuronal degeneration in dopaminergic neurons,23 normoglycemic animals were used in the present work to examine the
possible neuroprotective role of DPG against PD, independent
of its glucose-lowering eﬀects. 15 In fact, the use of
normoglycemic animals for examining DPG’s eﬀects has
been previously described in murine models of myocardial
infarction15 and PTZ-induced epilepsy.17 Of note, no
hypoglycemia or oﬀ-target gastrointestinal SGLT1 inhibition
has been reported in normoglycemic rats15,24 at the low dose
of DPG (1 (mg/kg)/day by gavage) which was used in the
present set of experiments.25

■

RESULTS
Dapagliﬂozin Treatment Attenuates Motor Dysfunction and Improves Motor Performance without Lowering Blood Glucose Levels in Normoglycemic Rats
with Rotenone-Induced PD. To explore the eﬀect of DPG
on the motor dysfunction triggered by rotenone, the motor
performance was assessed by the open-ﬁeld test, whereas the
motor coordination was examined using the rotarod test. In the
open-ﬁeld test, rotenone signiﬁcantly disturbed the motor
activity of rats, as evidenced by decline of the total traveled
distance (0.61-fold), mean speed (0.66-fold), line crossings
(0.70-fold), and rearing frequency (0.64-fold), along with an
obvious increase in the immobility time (1.8-fold), as
compared to the control rats. In the rotarod test, rotenone
suppressed the fall-oﬀ latency (0.58-fold; Figure 1A−G).
Interestingly, DPG improved the motor performance as
manifested by a prominent increase of the aforementioned
motor parameters by 220%, 290%, 210%, and 210%,
respectively, as compared to PD rats, together with a
diminution of the immobility time by 54.5%. Moreover,
DPG reverted the fall-oﬀ latency back to its normal values,
signifying the enhanced motor coordination and balance.
Track plots of animals in the open-ﬁeld corroborated these
ﬁndings (Figure 1F). Of note, the blood glucose levels were
not signiﬁcantly changed in rotenone or rotenone + DPG
groups (Figure 1H). This is consistent with the previous
literature that demonstrated no hypoglycemia in DPG-treated
normoglycemic rats at the dose of 1 mg/kg, by gavage.24
Consistent with the previous studies,15,24 we did not observe
any gastrointestinal tract (GIT) disturbance, e.g., soft stool or
diarrhea due to SGLT1 inhibition, conﬁrming the selective
SGLT2 inhibition at the used dose. Together, these ﬁndings
indicate that DPG treatment elicited beneﬁcial attenuation of
the motor dysfunction and enhanced the motor coordination
in rats with rotenone-induced PD.
C
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Figure 2. Dapagliﬂozin attenuates the neuronal degeneration and the histopathologic changes in the striata of rotenone-induced PD rats. (A−D)
Histopathologic assessment using H&E stain at ×400 magniﬁcation: (A) Representative photomicrograph of the striatum from the control group
depicting normal striatal morphology showing well-organized neurons demonstrating intact perikaryons with large vesicular nuclei and prominent
nucleoli (black arrows). Intact intercellular matrix with minimal glial-cell inﬁltrates is also evident. (B) Representative photomicrograph of the
striatum from the control + DPG group showing normal striatal structure with normal neurons and no histopathologic alterations. (C)
Representative photomicrograph of the striatum from the rotenone group showing wide diﬀuse areas of severe neuronal loss and damage with
many degenerated, shrunken, and pyknotic neurons that lost their subcellular details (red arrows). The photomicrograph also demonstrates
moderate perineuronal edema, moderate glial cell inﬁltrates (arrowheads), and moderate vacuolization of the intercellular matrix. (D)
Representative photomicrograph of the striatum from rotenone + DPG group showing attenuation of the histologic alterations with many
apparently intact neurons with preserved subcellular details (black arrows) and few scattered degenerative neurons (red arrows). An intact
intercellular matrix was observed with minimal records of reactive glial-cell inﬁltrates (arrowheads). (E−H) Neuron visualization by Nissl staining
at ×400 magniﬁcation: (E, F) Representative photomicrographs of the striata from the control and control + DPG groups, respectively, showing
intact neurons; (G) Representative photomicrograph of the striatum from the rotenone group showing a large proportion of degenerated neurons
with pyknotic alterations; (H) Representative photomicrograph of the striatum from the rotenone + DPG group showing preserved neuronal
integrity with a marked reduction of the degenerative neuronal records and higher records of intact neurons. (I) Assessment of the intact neuron
count in the striatum of Nissl-stained sections. Data are expressed as the mean ± SEM of number of intact neurons/ﬁeld for six nonoverlapping
ﬁelds/section; n = 6; *P < 0.05, statistical signiﬁcance against the control group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG,
dapagliﬂozin.

Dapagliﬂozin Treatment Mitigates the Neuronal
Degeneration and the Histopathologic Aberrations in
the Striata of Rats with Rotenone-Induced PD. We next
assessed whether DPG could protect the neuronal degeneration and the histopathologic changes in the striata of rats with
rotenone-induced PD. Sections of the control group as well as
the DPG-treated control exhibited an intact architecture of the
striatum showing normal neurons with intact perikaryons and
intact intercellular matrix with minimal glial cell inﬁltrates
(Figure 2A,B,E,F). Conversely, the rotenone group demonstrated severe neuronal loss (Figure 2C,G,I), with many
degenerated and pyknotic neurons and perineuronal edema
accompanied by moderate glial cell inﬁltrates and intercellular
matrix vacuolization. In line with the ﬁndings of the behavioral
tests, DPG treatment attenuated these histopathologic

aberrations and counteracted the degeneration of neurons
(Figure 2D,H,I).
Dapagliﬂozin Treatment Preserves the Dopaminergic Neurons, Lowers the Expression of α-Synuclein, and
Enhances the Striatal Dopamine Levels in Rats with
Rotenone-Induced PD. To characterize the molecular events
linked to the rotenone-induced PD pathology and associated
neuronal injury, the protein expression of tyrosine hydroxylase
(TH), the rate-limiting enzyme of neuronal dopamine
synthesis,1 was investigated. Meanwhile, the mRNA expression
of the neurotoxic α-synuclein, a hallmark protein aggregate
that has been linked to PD pathology,1 together with the
neuronal dopamine levels were explored. Immunoblotting
revealed that rotenone incurred a robust decline of TH
expression (0.13-fold), as compared to the control group
(Figure 3A,B). These data were corroborated by the
D
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Figure 3. Dapagliﬂozin reverses rotenone-induced alterations of tyrosine hydroxylase (TH), α-synuclein, and dopamine levels in PD rats. (A)
Protein expression of TH detected by immunoblotting. β-Actin was utilized as the loading control to prove equal protein loading. (B) TH relative
protein expression. The values were extracted from at least three independent experiments (presented as the mean ± SEM). (C) Representative
photomicrographs of the immunohistochemical evaluation of TH protein expression (magniﬁcation ×400). The control and control + DPG groups
show intense TH staining, while the rotenone group shows a lower intensity of TH-immune reactivity. The rotenone + DPG group demonstrates
reinstated TH protein expression. (D) Quantiﬁcation of TH immunostaining in the striatum. Values are the mean ± SEM of the area percentage of
TH-immune staining to the total area of the microscopic ﬁeld across six nonoverlapping ﬁelds/section; n = 6. (E) α-Synuclein relative mRNA
expression detected by RT-qPCR and GAPDH was used as the housekeeping gene. The relative expression was calculated from the 2−ΔΔCT
formula. (F) Dopamine levels. The values are the mean ± SEM; n = 6; *P < 0.05, statistical signiﬁcance against the control group; #P < 0.05,
statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

immunohistochemical detection of TH (Figure 3C,D). In the
same context, the neuronal mRNA expression of the
neurotoxic α-synuclein was increased (1.87-fold), ultimately
provoking a decrease of the striatal dopamine levels (0.29fold), as compared to the control group (Figure 3E and Figure
3F, respectively). The administration of DPG reversed these
events, as manifested by the normalization of TH levels,
suppression of α-synuclein expression by 34%, and enhancement of dopamine levels (221%), as compared to PD rats.
Together, these ﬁndings reveal that DPG protects dopaminergic neurons and lowers the neurotoxic α-synuclein with
consequent enrichment of the striatal dopamine levels, events

that are in line with the observed enhancement of the
functional motor activity and coordination of rats.
Dapagliﬂozin Treatment Inhibits Neuronal Oxidative
Changes and Restores DJ-1/Nrf2 Signaling in Rats with
Rotenone-Induced PD. Given the fact that ROS-associated
mitochondrial dysfunction/ATP depletion is a chief hallmark
that mediates the selective loss of dopaminergic neurons in
PD,3 we aimed to explore the antioxidant potential of DPG in
the striata of PD rats by examining the lipid peroxides and the
DJ-1 (PARK7)/Nrf2 signaling. Rotenone administration
enhanced the striatal oxidative aberrations, as evidenced by
increased lipid peroxide levels (4.3-fold), as compared to the
control rats (Figure 4). Interestingly, DPG attenuated lipid
E
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Figure 4. Dapagliﬂozin suppresses neuronal oxidative stress and restores the DJ-1/Nrf2 pathway in striata of rotenone-induced PD rats. (A) Lipid
peroxides expressed as MDA. (B) Nuclear Nrf-2 protein expression. (C) Western blotting depicting the protein expression of DJ-1 protein. β-Actin
served as the loading control. (D) DJ-1 relative protein expression. The values were extracted from at least three independent experiments
(presented as the mean ± SEM). (E) Heme oxygenase-1 (HO-1) levels. Values for lipid peroxides, Nrf2, and HO-1 are the mean ± SEM; n = 6; *P
< 0.05, statistical signiﬁcance against the control group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

peroxide levels by 56%, as compared to PD rats. To evaluate
whether the observed antioxidant actions of DPG are related to
the DJ-1/Nrf2 pathway, we investigated the expression of the
upstream signal Nrf2 and its stabilizer protein DJ-1. Meanwhile, the transcriptional activity of Nrf2 was detected by
measuring the levels of HO-1 protein. As displayed in Figure 4,
rotenone increased the nuclear Nrf2 levels (11-fold) and the
protein expression of DJ-1 (5.1-fold) and HO-1 (2.86-fold), as
compared to the control rats. In line with the attenuation of
lipid peroxides, DPG counteracted the changes of the DJ-1/
Nrf2 pathway, as evidenced by lowering the protein expression
of Nrf2, DJ-1, and HO-1 by 64.2%, 68.8%, and 53.8%,
respectively, as compared to PD rats. These ﬁndings indicate
that DPG’s antioxidant actions are implicated in the

amelioration of rotenone-induced neuronal injury and PD
pathology via the modulation of DJ-1/Nrf2 pathway.
Dapagliﬂozin Treatment Counteracts Neuronal
Apoptotic Events and Augments GDNF and Its Downstream PI3K/AKT/GSK-3β Signaling in the Striata of
Rats with Rotenone-Induced PD. To determine the eﬀects
of DPG on the apoptotic events in rotenone-induced PD in
rats, the mitochondrial energy markers ATP and ADP were
assessed along with the protein expression of Bax and cleaved
caspase-3. Rotenone triggered an impairment of the
mitochondrial energy generation, as evidenced by decreased
ATP (0.36-fold) and increased ADP levels (3.05-fold), as
compared to the control rats (Figure 5). In the same regard,
rotenone increased the protein expression of the proapoptotic
Bax (2.52-fold) and cleaved caspase-3 (2.32-fold), as compared
F
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Figure 5. Dapagliﬂozin reverses the ATP depletion and neuronal apoptotic cell death in the striata of rotenone-induced PD rats. (A) ATP levels.
(B) ADP levels. Values are the mean ± SEM; n = 6. (C) Western blotting depicting the protein expression of the proapoptotic Bax (upper panel)
and cleaved caspase-3 (middle panel). Equal protein loading was demonstrated using β-actin (lower panel). (D, E) Bax and cleaved caspase-3
relative protein expression, respectively. The values were extracted from at least three independent experiments (presented as the mean ± SEM);
*P < 0.05, statistical signiﬁcance against the control group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

augmenting the PI3K/AKT/GSK-3β pathway by increasing
the expression of PI3K, p-AKT/AKT, and p-GSK-3β (Ser9)/
GSK-3β by 480%, 528%, and 237%, respectively, as compared
to PD rats. Overall, these ﬁndings reveal the marked
antiapoptotic eﬀects of DPG, which were mediated, at least
partly, via upregulating the expression of GDNF and activating
the PI3K/AKT/GSK-3β pathway.
Dapagliﬂozin Treatment Suppresses the Neuroinﬂammation via Curbing of the Activation of the NF-κB
Pathway and Expression of TNF-α in the Striata of Rats
with Rotenone-Induced PD. To explore the neuronal
inﬂammatory events in PD rats, we investigated the activation
of the NF-κB pathway and the protein expression of the
downstream eﬀector TNF-α. The immunoblotting data
demonstrated that rotenone incited NF-κB activation as

to the control rats. Interestingly, DPG counteracted the
disruption of energy generation by increasing the ATP
production by 201% and it reversed the apoptotic aberrations
by downregulating the expression of Bax and cleaved caspase-3
by 50.6% and 54.8%, respectively, as compared to PD rats.
To further explore the underlying antiapoptotic mechanisms,
the striatal levels of GDNF and the signaling of its downstream
PI3K/AKT/GSK-3β pathway were detected. Rotenone
diminished the striatal expression of GDNF (0.51-fold) and
suppressed the PI3K/AKT/GSK-3β pathway, as evidenced by
downregulating the expression of PI3K (0.16-fold), p-AKT/
AKT ratio (0.18-fold), and p-GSK-3β Ser9/GSK-3β ratio
(0.36-fold), as compared to the control rats (Figure 6). In line
with the attenuation of apoptosis, DPG reversed the above
changes by increasing the expression of GDNF (173%) and
G
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Figure 6. Dapagliﬂozin enhances the GDNF levels and PI3K/AKT/GSK-3β signaling in the striata of rotenone-induced PD rats. (A) GDNF
relative mRNA expression detected by RT-qPCR and GAPDH was used as the housekeeping gene. The relative expression was calculated from the
2−ΔΔCT formula. Values are the mean ± SEM; n = 6. (B) Western blotting depicting the protein expression of the PI3K p110α, p-AKT(Ser473),
and total AKT (upper panel) alongside p-GSK-3β(Ser9) and total GSK-3β (lower panel). Equal protein loading was demonstrated using β-actin.
(C) PI3K relative protein expression. (D) p-AKT(Ser473) relative protein expression. (E) p-GSK-3β(Ser9) relative protein expression. The values
were extracted from at least three independent experiments (presented as the mean ± SEM); *P < 0.05, statistical signiﬁcance against the control
group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

underlying multifactorial pathology.3 Thus, the quest for
therapeutic interventions with multipronged eﬀects on PD
progression has been envisioned as an eﬃcient strategy. The
present study demonstrates, for the ﬁrst time, the beneﬁcial
eﬀects of DPG against rotenone-induced neuronal injury and
PD motor dysfunction in rats. Interestingly, DPG attenuated
the PD motor deﬁcits, histopathologic aberrations, and αsynuclein expression and preserved the striatal dopaminergic
neurons. Mechanistically, DPG inhibited neuronal ROS/
oxidative changes with consequent restoration of the DJ-1/
Nrf2 pathway. These events primed the counteraction of
neuronal apoptosis and boosting of the GDNF levels and
associated activation of the PI3K/AKT/GSK-3β pathway. In
tandem, DPG suppressed the neuroinﬂammation via inhibition
of the NF-κB pathway (Figure 8).
The current data demonstrated enhanced oxidative stress in
the striata of PD rats marked with increased lipid peroxide
levels and increased levels of DJ-1, nuclear Nrf2, and the
downstream signal HO-1. These ﬁndings are consistent with
previous reports26−29 that characterized an upregulated DJ-1

evidenced by increased protein expression of activated NFκBp65 (4.2-fold) and its phosphorylated form (p-NF-κBp65;
6.3-fold) together with increased expression of TNF-α (3.34fold), as compared to the control rats (Figure 7). These
ﬁndings were corroborated by the immunohistochemical
detection of activated NF-κBp65 that revealed an extensive
expression in the striata of PD rats (8.08-fold), as compared to
the control rats (Figure 7D,E). DPG counteracted these
alterations via downregulating the expression of NF-κBp65 and
p-NF-κBp65 by 66.9% and 73%, respectively, and TNF-α by
47.9%, as compared to PD rats. Meanwhile, DPG downregulated the immunohistochemical staining of NF-κBp65 by
67.7%, as compared to PD rats. These ﬁndings reinforce the
notion that DPG’s suppression of neuronal inﬂammation is
implicated in the attenuation of neuronal injury and rotenoneinduced PD pathology.

■

DISCUSSION
Current treatment strategies for PD are directed to alleviate the
symptomatic features of the disease without modifying its
H
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Figure 7. Dapagliﬂozin suppresses the activation of the NF-κB pathway and TNF-α level in the striata of rotenone-induced PD rats. (A) Western
blotting describing the expression of the phospho-NF-κBp65 and the nuclear NF-κBp65. Lamin B was utilized as loading control. (B, C) PhosphoNF-κBp65 and nuclear NF-κBp65 relative protein expression, respectively. The values were extracted from at least three independent experiments
(presented as the mean ± SEM). (D) Staining of NF-κBp65 protein expression detected by immunohistochemistry (the representative
photomicrographs are shown at 400× magniﬁcation). The control and control + DPG groups show minimal staining, while the rotenone group
shows strong positive staining. The rotenone + DPG group demonstrates attenuated expression of NF-κBp65 protein. (E) NF-κBp65
immunostaining quantiﬁcation in the striatum. Values are the mean ± SEM of area percentage of NF-κBp65 immunostaining to the total area of the
microscopic ﬁeld across six nonoverlapping ﬁelds/section; n = 6. (F) Tumor necrosis factor-α (TNF-α) levels. Values are the mean ± SEM; n = 6;
*P < 0.05, statistical signiﬁcance against the control group; #P < 0.05, statistical signiﬁcance against the rotenone group; DPG, dapagliﬂozin.

expression in response to rotenone treatment in vivo and in
vitro. In fact, upregulation28,29 and downregulation30,31 of the
Nrf2/HO-1 pathway have been described in the pathogenesis
of rotenone-induced PD model. When subjected to oxidative
stress, DJ-1 itself is oxidized at cysteine residues which enables
it to scavenge ROS. 28 Virtually, oxidative stress and
mitochondrial dysfunction play a pivotal role in the pathogenesis of PD in human patients and experimental models.29,32
DJ-1 is a redox-sensitive protein that protects neurons against
oxidative stress and cell death. Mutations of DJ-1 have been
associated with an early onset of PD symptoms, due to the
neurodegeneration of nigrostriatal dopaminergic neurons. At
the molecular level, DJ-1 serves as a stabilizer of Nrf2 by
disrupting the Keap1/Nrf2 complex and/or preventing the
interaction of Nrf2 with Keap1.33 Hence, it minimizes Nrf2
ubiquitination and 26S proteasomal degradation and thus
enhances its transactivation.27 Several lines of evidence have
characterized Nrf2 as a key interception point for the crosstalk
among diverse cytoprotective, antioxidant, and anti-inﬂammatory pathways.27 Nrf2 and its downstream signal HO-1 act as
sensors of the pro-oxidant stressors which are induced as a
compensatory mechanism to halt the deleterious eﬀects of
ROS and free radicals.34 Despite the observed upregulation of
Nrf2 in the rotenone-treated rat striata, oxidative stress was
obviously detected, as evidenced by increased lipid peroxides.

This can be attributed to the rotenone-induced lowering of the
inactive GSK-3β(Ser9), an event that has been described to
interfere with Nrf2 antioxidant action, likely via its nuclear
exclusion, thus impeding its transactivating function.35 In fact,
Nrf2 ablation has been reported to result in exaggerated
oxidative stress that drives activation of the redox-responsive
NF-κB and linked proinﬂammatory events, thereby pointing to
the interplay between Nrf2 and NF-κB cascades.34 In the same
context, the crosstalk between Nrf2/HO-1 and PI3K/AKT
pathway advocates that restraining Nrf2 activity negatively
aﬀects the PI3K/AKT pathway, culminating in neuronal
proapoptotic events.36 Conversely, AKT has been reported
to be engaged in the Nrf2 nuclear localization, conﬁrming the
mutual interaction between Nrf2 and AKT.27
Interestingly, DPG suppressed the oxidative changes and
restored the levels of DJ-1, Nrf2, and HO-1, pointing to its
signiﬁcant antioxidant eﬀects for attenuation of PD pathology
via the modulation of DJ-1/Nrf2 signaling. In fact, DPG has
demonstrated marked antioxidant eﬀects in obesity-induced
cognitive decline12 and myocardial infarction via suppression
of ROS.15 Given the fact that ROS are the main triggers for
upregulation of DJ-1/Nrf2, it may be straightforward to
understand that the observed DPG-induced restoration of
Nrf2/HO-1 pathway is secondary to the lowering of ROS and
the associated neuronal oxidative stress.34 In fact, the
I
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Figure 8. Summary of the underlying mechanisms for dapagliﬂozin’s amelioration of rotenone-induced neuronal injury and PD pathogenesis.
According to the current study ﬁndings, dapagliﬂozin, a selective SGLT2 inhibitor, attenuated the neuronal injury through the following actions:
(1) curbing the ROS/oxidative aberrations, an event that resulted in the restoration of the DJ-1/Nrf2 pathway and associated transactivation of
antioxidant response element (ARE) genes encoding HO-1 back to its normal levels. The attenuation of neuronal oxidative stress and ROS
production primed the counteraction of ROS-dependent apoptosis and neuroinﬂammation, as illustrated in steps 2 and 3. (2) Dampening the
apoptotic machinery and boosting the GDNF and associated activation of the prosurvival PI3K/AKT pathway with consequent inactivation of
GSK-3β (via Ser9 phosphorylation). (3) Suppression of the NF-κB pathway that resulted in lowered proinﬂammatory cytokine production (e.g.,
TNF-α) and neuroinﬂammation. Together, these events ultimately lowered the expression of the neurotoxic α-synuclein in the dopaminergic
neurons, thereby minimizing their loss. Black solid arrow, activate; red blunt arrow, inhibit; green dotted arrow, activating eﬀect of dapagliﬂozin;
green blunt arrow, inhibitory eﬀect of dapagliﬂozin.

play a pivotal role in the pathogenesis of neurodegenerative
diseases, such as PD since adequate energy supply to the CNS
is crucial for neuronal survival and excitability.3,41 In the
context of apoptotic events, an enhanced expression of the
cleaved caspase-3 has been described in post-mortem PD
patients and rodent models of PD.42,43 Meanwhile, the current
data revealed that rotenone lowered the levels of the
neurotrophic factor GDNF and disrupted its downstream
PI3K/AKT/GSK-3β signaling in the striata of rats. In the
context of apoptosis, the dysregulation of PI3K/AKT/GSK-3β
pathway has been reported to play a crucial role in PD
pathology.3,7 The PI3K/AKT pathway has been reported to
inactivate the proapoptotic/proinﬂammatory GSK-3β via its
Ser9 phosphorylation. The dysregulation of PI3K/AKT
signaling has been described in post-mortem dopaminergic
neurons of PD patients where low p-AKT/AKT levels were
detected.6 In this regard, α-synuclein has been suggested as a
causative signal for activating the proapoptotic/proinﬂammatory GSK-3β (via its Tyr216 phosphorylation) in the striatum
of post-mortem PD patients and transgenic PD mice.3,44 In
addition, the overexpression of active GSK-3β in mitochondria
has been reported to disrupt ATP generation, enhance
oxidative stress, and exacerbate the apoptotic eﬀects of
rotenone via promoting of cytochrome c release and caspase3 activation.45
Interestingly, DPG hampered the apoptotic machinery,
upregulated the upstream GDNF, and activated the prosurvival
PI3K/AKT pathway with consequent inactivation of GSK-3β
(via Ser9 phosphorylation). These pleiotropic antiapoptotic
actions of DPG are in line with its reported suppression of
neuronal apoptosis in obesity-induced cognitive decline via
diminishing Bax levels and rectifying mitochondrial dysfunction.12 The multipronged antiapoptotic actions of DPG are
mainly ascribed to the observed boosting of the neurotrophic

mitigation of neuronal oxidative stress by DPG accentuates the
crucial role of its antioxidant features for ameliorating PD
neurodegeneration and is likely due to the observed DPGinduced inactivation of GSK-3β (via its phosphorylation at
Ser9) and suppression of the NF-κB pathway. In this context,
the observed inactivation of GSK-3β by DPG is plausibly a key
player in the suppression of neuronal oxidative stress, since
GSK-3β blockade has been proven to alleviate oxidative
damage in several neuronal models.3,7 Meanwhile, the
observed DPG-evoked suppression of the NF-κB pathway
also contributes to curtailing neuronal oxidative stress elicited
by the pro-oxidant features of NF-κB in PD models.37
Interestingly, previous reports have revealed that substantia
nigra dopaminergic neurons can be protected via the Nrf2
pathway and p62-associated autophagy activation.38 In fact,
autophagy has been reported to exert antioxidant actions in PD
via the removal of oxidized/dysfunctional cellular organelles
and proteins.39 Moreover, the interventions that restore the
balance between autophagy and apoptosis have been proven
eﬀective for combating the neuropathological changes in
rotenone-induced PD model.39,40 In this context, dopaminergic neuron loss in the substantia nigra has been halted via
enhancing Ser70 phosphorylation of Bcl-2 and the subsequently increased autophagy/apoptosis ratio.40 Notably,
additional studies exploring the detailed eﬀects of dapagliﬂozin
on autophagy and associated mechanisms are requested.
The present ﬁndings further demonstrated a disrupted
mitochondrial ATP production and enhanced apoptosis in the
striata of rotenone-induced PD, as evidenced by upregulated
expression of the proapoptotic Bax and cleaved caspase-3.
These apoptotic events are likely driven by the exaggerated
neuronal oxidative stress and proinﬂammatory reactions.26 In
fact, excessive mitochondrial ROS generation impairs the
respiratory chain function and ATP generation, events that
J
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Table 1. Experimental Design and Study Groupsa
group
Group I (control)
Group II (control + DPG)
Group III (rotenone)
Group IV (rotenone + DPG)

description
Group I (control) received 11 subcutaneous injections of 1% (v/v) DMSO (0.2 mL/kg) on an alternate-day basis corresponding
to rotenone administration days for groups III and IV, in addition to normal saline (5 mL/kg) by gavage daily for 3 weeks
starting from the ﬁrst day to serve as the control group.
Group II (control + DPG) received 11 subcutaneous injections of 1% DMSO (0.2 mL/kg) on an alternate-day basis
corresponding to rotenone administration days for groups III and IV, in addition to DPG suspended in normal saline (1 (mg/
kg)/day; 5 mL/kg) by gavage 16 for 3 weeks starting from the ﬁrst day to serve as the drug control group.
Group III (rotenone) received 11 subcutaneous injections of rotenone (1.5 mg/kg; 0.2 mL/kg) dissolved in 1% DMSO every
other day,50 in addition to normal saline (5 mL/kg) by gavage daily for 3 weeks starting from the ﬁrst day.
Group IV (rotenone + DPG) received 11 subcutaneous injections of rotenone (1.5 mg/kg; 0.2 mL/kg) dissolved in 1% DMSO
every other day, in addition to a daily dose of DPG (1 mg/kg; 5 mL/kg) by gavage for 3 weeks, starting from the ﬁrst day, 1 h
before the rotenone injection on the days of rotenone administration.

a

DMSO, dimethyl sulfoxide; DPG, dapagliﬂozin.

neurotoxicity via the blockade of microglial activation.7,49 The
observed DPG-induced activation of the upstream PI3K/AKT
signaling may also participate in the suppression of neuronal
inﬂammation since the AKT kinase is responsible for Ser9
phosphorylation/inactivation of GSK-3β which ultimately
suppresses the proinﬂammatory NF-κB signaling.3

factor GDNF and the subsequent activation of the PI3K/AKT
pathway. Conceptually, therapeutic interventions that activate
PD neuronal PI3K/AKT pathway have been reported to aﬀord
marked neuroprotection in several neurodegenerative models,
including PD.3 A mutual interplay has been described between
neurotrophic factors, e.g., GDNF and AKT where some
protective actions of GDNF are achieved through the AKT
signaling.3 Conversely, AKT activation has been reported to
upregulate the expression of GDNF.46 The current observation
that DPG inactivated GSK-3β, via its Ser9 phosphorylation,
may also point to its eﬀective role for the abrogation of αsynuclein-induced neurotoxicity and cell death.3,46 Several in
vitro as well as in vivo studies conﬁrmed that the blockade of
GSK-3β is an eﬀective tool against dopaminergic neurodegeneration via multipronged moderation of several pathogenic targets, e.g., neuronal oxidative stress, inﬂammatory
signals, along with mitochondrial dysfunction and associated
apoptosis.3
The current data revealed that PD rats demonstrated
marked neuronal inﬂammation evidenced by the activation
of NF-κB signaling/upregulation of its downstream eﬀector
TNF-α, ﬁndings that are consistent with previous studies.5,37
Notably, TNF-α can bind to the TNF receptor (TNFR),
culminating in NF-κB pathway activation.37,47 Ample evidence
has revealed that α-synuclein drives persistent inﬂammatory
responses and glial cell activation with consequent degeneration of the dopaminergic neurons in PD patients and animal
models.5,37 In this regard, NF-κB is a key proinﬂammatory
pathway that provokes neuroinﬂammation in response to
excessive ROS, proinﬂammatory cytokines, and GSK-3β
activation.37,47 It has been reported that p-GSK-3β (Tyr216)
triggers the activation of NF-κB signaling and associated
transcription of several proinﬂammatory signals via IκB kinase
(IKK)-induced phosphorylation and degradation of the IκB
inhibitory subunit.3 Of note, the glial-cell-driven proinﬂammatory events may contribute to neuronal oxidative damage via
overshooting of the neurotoxic ROS and prostaglandins, which
ultimately elicit neuronal death.48
Remarkably, DPG elicited signiﬁcant anti-inﬂammatory
actions via curbing neuronal NF-κB activation and its
downstream signal, TNF-α. These anti-inﬂammatory eﬀects
are in accord with previous studies. 15 The observed
suppression of GSK-3β (via Ser9 phosphorylation) may
contribute to the extenuation of neuronal inﬂammation. This
can be conceived from the fact that the GSK-3β inhibitor,
lithium chloride, has been reported to repress proinﬂammatory
signals, including TNF-α, and promote the production of the
anti-inﬂammatory IL-10 in PD models.3,49 GSK-3β inhibition
has also been proven to be eﬀective against 6-OHDA-induced

■

CONCLUSION
For the ﬁrst time, the current ﬁndings reveal that dapagliﬂozin,
independent of its glucose-lowering eﬀects, has demonstrated
neuroprotective actions against rotenone-evoked neuronal
injury and PD motor dysfunction in rats. These beneﬁcial
eﬀects were chieﬂy elicited via suppression of neuronal
oxidative stress and associated restoration of the DJ-1/Nrf2
pathway. The attenuation of ROS production primed the
counteraction of apoptosis, boosting GDNF and associated
PI3K/AKT/GSK-3β signaling alongside the suppression of
NF-κB-linked neuroinﬂammation. Together, the current data
recommend that dapagliﬂozin may oﬀer a promising
intervention for mitigating the neuropathological aberrations
of PD, which may be useful in type II diabetes mellitus patients
with coexisting PD. Prospective studies are warranted to gain
further insights into the exact molecular mechanisms and
signaling networks implicated in dapagliﬂozin’s neuroprotective actions, in particular, the autophagy-related mechanisms.
Moreover, it would be advisible to test the potential eﬃcacy of
dapagliﬂozin for combating the manifestations of PD in the
clinical setting, especially in type II diabetic patients with
coexisting PD.

■

MATERIALS AND METHODS

Drugs and Chemicals. Dapagliﬂozin was obtained from
AstraZeneca (Cairo, Egypt). Rotenone and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA). All other chemicals were of pure analytical grade.
Animals. The present study was conducted with adult male Wistar
rats, weighing 230 ± 20 g, which were obtained from the laboratory
animal farm of the Egyptian Organization for Biological Products and
Vaccines (VACSERA), Cairo, Egypt. The animals were accommodated in the animal facility of Faculty of Pharmacy, Cairo University,
under controlled environmental conditions, including a temperature
of 25 ± 2 °C, 60 ± 10% humidity, and a 12/12 h light/dark cycle, and
were allowed free access to standard rodent chow diet and water.
Ethical Approval. All animal handling and testing procedures
abided by the regulations set in the Guide for the Care and Use of
Laboratory Animals issued by the U.S. National Institutes of Health
(NIH Publication No. 85-23, revised 1996) and were approved by the
Research Ethics Committee of Faculty of Pharmacy, Cairo University
(REC-FOPCU, Permit Number BC 2717).
Experimental Design. The rats were allowed to acclimatize for 1
week before starting the study which spanned over a total period of 21
K
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Table 2. List of Primer Sequences Used in the Real-Time qPCR Analysisa
gene

primer sequence

accession number

α-synuclein

F: 5′-CCCTAGCAGTGAGGCTTATGA-3′
R: 5′-CACAGCACATCATTCTTCTTAG-3′
F: 5′-TAGAAGGCTGGTGAGTGACAAAGTA-3′
R: 5′-TCATCTAAAAACGACAGGTCATCATC-3′
F: 5′-TTGGTATCGTGGAAGGACTCA-3′
R: 5′-TGTCATCATATTTGGCAGGTTT-3′

NM_019169.2

GDNF
GAPDH

NM_019139.1
NM_017008.4

a

GDNF, glial-cell-line-derived neurotrophic factor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Enzyme-Linked Immunosorbent Assay of Striatal Dopamine, ADP, ATP, MDA, TNF-α, Nrf2, and HO-1 Levels. The
striatal homogenate was used for the determination of dopamine,
ADP, ATP, lipid peroxides (malondialdehyde, MDA), tumor necrosis
factor-α (TNF-α), nuclear factor erythroid 2-related factor (Nrf2),
and heme oxygenase-1 (HO-1) levels by enzyme-linked immunosorbent assay (ELISA) technique. The dopamine neurotransmitter
and the proinﬂammatory TNF-α were quantiﬁed using ELISA kits
(catalog numbers CSB-E08660r and CSB-E11987r, respectively)
purchased from Cusabio (Wuhan, China). The levels of the energy
markers, ADP and ATP were determined using ELISA kits (catalog
numbers MBS744390 and MBS723034, respectively) purchased from
MyBioSource (San Diego, CA, USA). The assay kit for ADP is
speciﬁc for ADP without cross-reacting with other ADP analogues,
and it oﬀers a sensitivity of 0.1 ng/mL as the minimum limit of
detection. Likewise, the ATP ELISA kit is selective for ATP without a
cross-reaction with ATP analogues and shows a 1 ng/mL as the
minimum level of sensitivity. The striatal MDA content was assessed,
as an index of lipid peroxidation, by an ELISA kit (catalog number LSF28018) obtained from LifeSpan BioSciences (Seattle, WA, USA).
Assay of the redox-sensitive transcription factor, Nrf2 was carried out
in the striatal nuclear extract using an ELISA kit (catalog number
600590) from Cayman Chemical (MI, USA). The nuclear fraction
was isolated from the striatal tissue homogenate using a nuclear
extraction kit (catalog number 10009277) provided by Cayman
Chemical (MI, USA). The Nrf2-regulated downstream HO-1 protein
expression was assayed using an ELISA kit (catalog number MK124)
procured from Takara Bio Inc. (Shiga, Japan). The ADP, ATP, and
MDA ELISA kits applied the competitive enzyme immunoassay
technique. Dopamine, TNF-α, and HO-1 assays employed the
quantitative sandwich enzyme immunoassay technique. The Nrf2
ELISA technique detected the speciﬁc DNA binding activity of the
transcription factor in the nuclear extract by capturing the
transcription factor using an immobilized speciﬁc double-stranded
DNA (dsDNA) sequence containing the Nrf2 response element. The
unknown concentrations were determined by interpolation from the
corresponding calibration curves relating the generated color
intensities to known standard concentrations. The results are
expressed as ng/mg tissue for dopamine, Nrf2, and HO-1 levels,
ng/g tissue for ADP, ATP and MDA levels, and pg/g tissue for TNFα content. All procedures were carried out in accordance with the
manufacturers’ guidelines.
Gene Expression Analysis of Striatal α-Synuclein and
GDNF. The mRNA expression levels of α-synuclein and the glialcell-line-derived neurotrophic factor (GDNF) were analyzed in the
brain striatum by qRT-PCR.56 Total RNA was isolated from striatal
tissues using the standard TRIzol reagent extraction method (catalog
number 15596-026, Invitrogen, Germany) according to the
manufacturer’s instructions. The purity of the extracted RNA was
assessed by the 260/280 nm ratio, and its integrity was conﬁrmed by
ethidium bromide stain analysis of 28S and 18S bands by
formaldehyde-containing agarose gel electrophoresis. Thereafter, the
isolated RNA was reverse transcribed into complementary DNA
(cDNA) using a RevertAid ﬁrst strand cDNA synthesis kit (MBI
Fermentas, Germany), in compliance with the manufacturer’s
protocol. To evaluate the expression of α-synuclein and GDNF
genes, qRT-PCR was carried out using SYBR Premix Ex Taq II
(Takara, Japan) in accordance with the manufacturer’s guidelines. In

days. The rats were randomly assigned into four groups (n = 18 each),
as described in Table 1.
The dose of DPG was selected based on previous reports in the
literature that demonstrated the alleviation of cognitive decline in
HFD-fed rats and PTZ-induced epilepsy.16,17 Moreover, on the basis
of the human equivalent dose (HED) calculation method,51 the
selected dose for rats (1 (mg/kg)/day, po) is quite consistent with the
commonly used dose of DPG in the clinical practice for humans. The
selected dose of rotenone is in harmony with previous reports26,52
that characterized the 1.5 mg/kg dose of rotenone as a reliable dose
for induction of consistent PD manifestations in rats. Herein, male
rats were used to conduct the current experimental protocol since
male rats have been reported to be more sensitive to the induction of
rotenone-induced Parkinson’s manifestations and associated histopathological ﬁndings than female rats.53
Blood Glucose Assessment. Twenty-four hours after the last
rotenone dose, blood samples were obtained through tail vein
puncture and were analyzed by a portable glucometer (AccuCheck
Performa, Roche Diagnostics, USA).
Behavioral Assessment. Following blood glucose measurement,
all rats were tested for motor perturbations using the open-ﬁeld and
rotarod tests, as follows:
Open-Field Test. The open-ﬁeld test was carried out to examine
the spontaneous locomotor activity of rats. The test was carried out
using a square wooden box (80 cm × 80 cm × 40 cm) with red walls
and a white smooth polished ﬂoor divided by black lines into 16 equal
squares 4 × 4. The test was performed under dim white light in a
quiet room, and an overhead camera was used to monitor the animals.
Each rat was gently placed in the center of the open-ﬁeld and was
allowed to freely explore the area for 5 min. The ﬂoor and walls were
thoroughly wiped after each tested animal to eliminate possible bias
due to odors left by previous rats.54 Total distance traveled, mean
speed, line crossings, rearing frequency, and immobility time were
recorded using ANY-maze behavioral tracking software (Stoelting,
CO, USA).
Rotarod Test. Rats were screened for motor coordination and
balance using rotarod apparatus (120 cm long and 3 cm in diameter
which rotates at a constant speed of 20 rpm). Before experimental
procedures, rats were habituated to maintain posture on the rotarod
by three training sessions, 5 min each, on 3 consecutive days. After
accomplishing the open-ﬁeld test, rats were allowed to move over the
rotarod and the latency until falling was recorded using a cutoﬀ limit
of 300 s.55
Brain Tissue Processing. After the evaluation of motor
performance, rats in each group were split into three sets and then
were sacriﬁced by decapitation under light anesthesia. Immediately
after decapitation, brains were rapidly dissected and washed with icecold saline. In the ﬁrst set (n = 6 per group), brains were instantly
ﬁxed in 10% (v/v) neutral buﬀered formalin for 72 h to perform
histopathologic and immunohistochemical examinations. In the
second and third sets, both striata were excised from each brain
under ice-cold conditions and then stored at −80 °C for biochemical
and molecular analyses. In the second set (n = 6 per group), the
striata were homogenized in ice-cold phosphate buﬀered saline (PBS),
and the striatal homogenate was used for enzyme-linked immunosorbent assay (ELISA) analyses. In the third set (n = 6 per group),
striatal tissues were used for gene expression and Western blot
analyses.
L
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brief, qRT-PCR reactions were conducted in 25 μL of reaction
mixtures containing 5 μL of cDNA, 12.5 μL of SYBR Premix Ex TaqII
reagent, 0.5 μL of 0.2 μM of each primer, and 6.5 μL of RNase-free
water. The primer sequences used are listed in Table 2. The PCR
protocol comprised 10 min at 95 °C for initial DNA polymerase
activation, followed by 40 cycles of denaturation at 95 °C for 15 s, and
annealing/extension at 60 °C for 60 s. The relative expression of the
target genes was calculated by the comparative cycle threshold (CT)
method using the 2−ΔΔCT formula, where glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a housekeeping gene.
Western Blot Analysis of Striatal TH, p-NF-κBp65/NFκBp65, DJ-1, Bax, Cleaved Caspase-3, PI3K, p-AKT/AKT, and
p-GSK-3β (Ser9)/GSK-3β Protein Expression. The protein
extraction process for the whole tissue lysate of the striatum and
the Western blotting were carried out as previously described.57 In
addition, the nuclear fraction lysate was obtained with the aid of
Cayman nuclear extraction kit (catalog number 10009277; Ann
Arbor, MI, USA). Equal amounts of protein lysates were resolved by
SDS−PAGE and were transferred to PVDF membranes. After
blocking with 5% bovine serum albumin (BSA), the target proteins
were probed with the corresponding primary antibodies overnight at 4
°C: tyrosine hydroxylase (TH), phospho-nuclear factor κB (p-NFκBp65 (Ser536)), nuclear factor κB (NF-κBp65), DJ-1, Bcl-2
associated x protein (Bax), cleaved caspase-3, phosphoinositide 3kinase (PI3K p110α), phospho-protein kinase B (p-AKT (Ser473)),
total protein kinase B (AKT), phospho-glycogen synthase kinase-3β
(p-GSK-3β (Ser9)), total glycogen synthase kinase-3β (GSK-3β)
(Cell Signaling Technology, USA). β-Actin was used as the loading
control for the whole tissue lysate, whereas lamin B served as the
loading control for the nuclear fraction lysate (Cell Signaling
Technology, USA). Membranes were incubated with the appropriate
horseradish peroxidase (HRP)-labeled secondary antibody, and the
target proteins were visualized using Biorad ECL solution (Biorad,
CA, USA). ImageJ software (Bethesda, MD, USA) was used for band
quantiﬁcation.
Histopathologic and Immunohistochemical Examinations.
Formalin-ﬁxed brain sections were trimmed and processed for paraﬃn
embedding by dehydration in serial dilutions of ethanol, clearing in
xylene, inﬁltration, and embedding into Paraplast tissue embedding
media. 4 μm thick sagittal brain sections were cut by a rotatory
microtome for the demonstration of the striatal region. Sections were
then stained with hematoxylin and eosin (H&E) for general
morphological examination by the light microscope as described.58
For the demonstration of intact and damaged neurons in the striatum,
tissue sections were stained with toluidine blue (Nissl stain), then six
randomly selected nonoverlapping ﬁelds per tissue section were
evaluated for quantiﬁcation of intact neurons in the striatum.
The striatal expression of TH and NF-κBp65 was assessed by the
immunohistochemical staining of paraﬃn-embedded brain sections as
reported.59 Brieﬂy, the deparaﬃnized tissue sections were pretreated
with 0.03% trypsin at 37 °C for 1 h for antigen retrieval, followed by
0.3% H2O2 for 20 min to quench endogenous peroxidase activity.
Subsequently, the tissue sections were blocked with 5% BSA for 30
min and then incubated overnight at 4○C with a rabbit monoclonal
anti-TH antibody (EP1532Y; catalog number ab137869, Abcam, MA,
USA) or a rabbit polyclonal anti-NF-κB p65 antibody (catalog
number RB-1638-P0, Thermo Fisher Scientiﬁc, CA, USA), diluted
1:100 followed by washing with PBS. The sections were then
incubated with HRP-conjugated secondary antibody (EnVision kit,
Dako, Copenhagen, Denmark) for 20 min. After another washing, the
immune reaction was detected by incubation with 3,3′-diaminobenzidine chromogen (Dako, Copenhagen, Denmark) for 15 min. After a
ﬁnal wash with PBS, the slides were counterstained with hematoxylin,
dehydrated, and cleared in xylene for light microscopic examination.
The percentage of the diaminobenzidine-immunopositive area to the
total area of the microscopic ﬁeld was computed for six randomly
selected nonoverlapping ﬁelds per tissue section. All microscopic
examinations and image analyses were performed using Leica
Application module for histological analysis attached to a full HD

Research Article

microscopic imaging system (Leica Microsystems GmbH, Wetzlar,
Germany).
Statistical Analysis. Data were tested for normality by the
Shapiro−Wilk normality test. Parametric data are expressed as the
mean ± standard error of the mean (SEM), and statistical
comparisons among the means were performed by one-way analysis
of variance (ANOVA), followed by Tukey’s post hoc multiple
comparisons test. The rearing frequency and the number of line
crossings are represented as median (with interquartile range) and
were statistically analyzed using Kruskal−Wallis nonparametric test,
followed by Dunn’s multiple comparisons test. All the statistical
analyses were conducted using GraphPad Prism software, version 7.04
(San Diego, CA, USA). Variations between groups were regarded as
statistically signiﬁcant at P < 0.05.
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